(NASDAQ: HOTH) Hoth Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.66%.
Hoth Therapeutics's earnings in 2026 is -$12,469,302.On average, 3 Wall Street analysts forecast HOTH's earnings for 2026 to be -$9,783,855, with the lowest HOTH earnings forecast at -$9,400,174, and the highest HOTH earnings forecast at -$10,071,615. On average, 3 Wall Street analysts forecast HOTH's earnings for 2027 to be -$11,607,964, with the lowest HOTH earnings forecast at -$11,152,749, and the highest HOTH earnings forecast at -$11,949,374.
In 2028, HOTH is forecast to generate -$19,733,538 in earnings, with the lowest earnings forecast at -$18,959,674 and the highest earnings forecast at -$20,313,936.